pharmaphorum

JANUARY 9, 2023

Novartis’ programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. ” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1

Side effects 113

Side effects Patients Management Marketing 113

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Oral therapy data presented at ASH. CellCentric, a U.K-based

Side effects 52

Side effects Patients Medical Medicine 52

pharmaphorum

AUGUST 21, 2022

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. In this product, bupropion is designed to increase levels of dextromethorphan in the blood and extend its half-life.

FDA 90

FDA Marketing Pharma Sales 90

pharmaphorum

OCTOBER 3, 2022

Following news of Relyvrio’s $158,000 annual price tag, both ALS advocates and outside observers have voiced outrage at the cost. After an average of about three years of therapy, you’ll have paid upwards of half a million dollars for five months of additional life.”. It can lead to progressive paralysis and death.

Insurance 52

Insurance Prescription FDA Patients 52

European Pharmaceutical Review

MAY 11, 2023

Novartis shared long-term data for its SMA gene therapy in March 2023, which indicated significant long-term motor-milestone achievements in spinal muscular atrophy (SMA). There are three modes of action (MOA) available for treatments – intrathecal injection, intravenous infusion and an oral formula.

Food and Drug Administration 70

Food and Drug Administration Government Healthcare Healthcare 70